Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies

International Journal of Radiation Oncology Biology Physics

Volumn 95, Issue 5, 2016, Pages 1357-1366

  Zhao, Jing ^a,b   Yorke, Ellen D ^c   Li, Ling ^a,d   Kavanagh, Brian D ^e   Li, X Allen ^f   Das, Shiva ^g   Miften, Moyed ^e   Rimner, Andreas ^c   Campbell, Jeffrey ^a   Xue, Jinyu ^h   Jackson, Andrew ^c   Grimm, Jimm ⁱ   Milano, Michael T ^j   Spring Kong, Feng Ming ^a,k  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e UNIVERSITY OF COLORADO   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Holy Redeemer Home Health and Hospice Care   (United States)

^j UNIVERSITY OF ROCHESTER   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DOSIMETRY; TOXICITY; TUMORS;

CONFIDENCE INTERVAL; LUNG DOSIMETRY; LUNG TOXICITIES; MEAN LUNG DOSE; METHODS AND MATERIALS; RADIATION-INDUCED; SMALL CELL LUNG CANCERS; STEREOTACTIC BODY RADIATION THERAPY;

RADIOTHERAPY;

AGE; AGED; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSIMETRY; EARLY CANCER; FEMALE; HUMAN; LUNG CANCER; LUNG FIBROSIS; LUNG METASTASIS; LUNG TOXICITY; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INDUCED LUNG TOXICITY; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; THORAX; AGE DISTRIBUTION; CARCINOMA, NON-SMALL-CELL LUNG; CAUSALITY; COMORBIDITY; INCIDENCE; LUNG NEOPLASMS; META ANALYSIS; MIDDLE AGED; MORTALITY; RADIATION PNEUMONITIS; RADIATION RESPONSE; RADIOSURGERY; RADIOTHERAPY DOSAGE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CAUSALITY; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOSURGERY; RADIOTHERAPY DOSAGE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84990847965     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.03.024     Document Type: Conference Paper

References (52)

1. 1 Baumann, P., Nyman, J., Hoyer, M., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27 (2009), 3290–3296.
2. 2 Zheng, X., Schipper, M., Kidwell, K., et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis. Int J Radiat Oncol Biol Phys 90 (2014), 603–611.
3. 3 Oh, D., Ahn, Y.C., Seo, J.M., et al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol 51 (2012), 596–602.
4. 4 Yu, W., Tang, L., Lin, F., et al. Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma. Int J Oncol 44 (2014), 1091–1098.
5. 5 Tree, A.C., Khoo, V.S., Eeles, R.A., et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14 (2013), e28–e37.
6. 6 Rusthoven, K.E., Kavanagh, B.D., Burri, S.H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27 (2009), 1579–1584.
7. 7 Lo, S.S., Moffatt-Bruce, S.D., Dawson, L.A., et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 8 (2011), 405–416.
8. 8 Chang, J.Y., Senan, S., Paul, M.A., et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncol 16 (2015), 630–637.
9. 9 Yamashita, H., Nakagawa, K., Nakamura, N., et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol, 2, 2007, 21.
10. 10 Ricardi, U., Filippi, A.R., Guarneri, A., et al. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol 48 (2009), 571–577.
11. 11 Barriger, R.B., Forquer, J.A., Brabham, J.G., et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 82 (2012), 457–462.
12. 12 Ueki, N., Matsuo, Y., Togashi, Y., et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 10 (2015), 116–125.
13. 13 Takeda, A., Kunieda, E., Takeda, T., et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 70 (2008), 1057–1065.
14. 14 Nagata, Y., Hiraoka, M., Mizowaki, T., et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 75 (2009), 343–347.
15. 15 Allibhai, Z., Taremi, M., Bezjak, A., et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87 (2013), 1064–1070.
16. 16 Takeda, A., Sanuki, N., Enomoto, T., et al. Subclinical interstitial lung disease: Is it a risk factor for fatal radiation pneumonitis following stereotactic body radiotherapy?. Lung Cancer, 83, 2014, 112.
17. 17 Inoue, T., Katoh, N., Onimaru, R., et al. Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer. Radiat Oncol, 8, 2013, 69.
18. 18 Chang, J.Y., Li, Q.Q., Xu, Q.Y., et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: How to fly in a “no fly zone.”. Int J Radiat Oncol Biol Phys 88 (2014), 1120–1128.
19. 19 Yamaguchi, S., Ohguri, T., Ide, S., et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis. Lung Cancer 82 (2013), 260–265.
20. 20 Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
21. 21 Guckenberger, M., Baier, K., Polat, B., et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 97 (2010), 65–70.
22. 22 Duncker-Rohr, V., Nestle, U., Momm, F., et al. Stereotactic ablative radiotherapy for small lung tumors with a moderate dose: Favorable results and low toxicity. Strahlenther Onkol 189 (2013), 33–40.
23. 23 Hayashi, S., Tanaka, H., Kajiura, Y., et al. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol, 9, 2014, 138.
24. 24 Timmerman, R., McGarry, R., Yiannoutsos, C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24 (2006), 4833–4839.
25. 25 Wu, A.J., Williams, E., Modh, A., et al. Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiother Oncol 112 (2014), 267–271.
26. 26 Modh, A., Rimner, A., Williams, E., et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 90 (2014), 1168–1176.
27. 27 Schanne, D.H., Nestle, U., Allgauer, M., et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: A multicenter analysis. Strahlenther Onkol 191 (2015), 125–132.
28. 28 Cuaron, J.J., Yorke, E.D., Foster, A., et al. Stereotactic body radiation therapy for primary lung cancers >3 centimeters. J Thorac Oncol 8 (2013), 1396–1401.
29. 29 Takeda, A., Kunieda, E., Ohashi, T., et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 141 (2012), 858–866.
30. 30 Yamashita, H., Kobayashi-Shibata, S., Terahara, A., et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol, 5, 2010, 32.
31. 31 Yamashita, H., Takahashi, W., Haga, A., et al. Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol 6 (2014), 708–715.
32. 32 Kanemoto, A., Matsumoto, Y., Sugita, T., Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer. Int J Clin Oncol 20 (2015), 680–685.
33. 33 Vogelius, I.S., Westerly, D.C., Cannon, G.M., et al. Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta Oncol 49 (2010), 1052–1057.
34. 34 Mayyas, E., Brown, S., Liu, J., et al. SU-E-T-289: Dose-volume-effect relationships for lung cancer patients treated with SBRT on a prospective protocol. Med Phys, 42, 2015, 3399.
35. 35 Ohashi, T., Takeda, A., Shigematsu, N., et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 62 (2005), 1003–1008.
36. 36 Onishi, H., Araki, T., Shirato, H., et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101 (2004), 1623–1631.
37. 37 Rowe, B.P., Boffa, D.J., Wilson, L.D., et al. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 7 (2012), 1394–1399.
38. 38 Chang, J.Y., Liu, H., Balter, P., et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol, 7, 2012, 152.
39. 39 Takeda, A., Oku, Y., Sanuki, N., et al. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume. J Radiat Res 55 (2014), 988–995.
40. 40 Oku, Y., Takeda, A., Kunieda, E., et al. Analysis of suitable prescribed isodose line fitting to planning target volume in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Pract Radiat Oncol 2 (2012), 46–53.
41. 41 Baker, R., Han, G., Sarangkasiri, S., et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys 85 (2013), 190–195.
42. 42 Takeda, A., Ohashi, T., Kunieda, E., et al. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours. Br J Radiol 85 (2012), 636–642.
43. 43 Chang, J.Y., Liu, H., Balter, P., et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol, 7, 2012, 152.
44. 44 Kanemoto, A., Matsumoto, Y., Sugita, T., Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer. Int J Clin Oncol 20 (2015), 680–685.
45. 45 Baba, F., Shibamoto, Y., Ogino, H., et al. Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiat Oncol, 5, 2010, 81.
46. 46 Bral, S., Gevaert, T., Linthout, N., et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: Results of a phase ii trial. Int J Radiat Oncol Biol Phys 80 (2011), 1343–1349.
47. 47 Guckenberger, M., Heilman, K., Wulf, J., et al. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): Results of a serial follow-up CT study. Radiother Oncol 85 (2007), 435–442.
48. 48 Guckenberger, M., Baier, K., Polat, B., et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 97 (2010), 65–70.
49. 49 Lee, D.S., Kim, Y.S., Yoo Ie, R., et al. Long-term clinical experience of high-dose ablative lung radiotherapy: High pre-treatment [18f] fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome. Lung Cancer 80 (2013), 172–178.
50. 50 Mangona, V.S., Aneese, A.M., Marina, O., et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: A propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys 91 (2014), 124–132.
51. 51 Schanne, D.H., Nestle, U., Allgauer, M., et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: A multicenter analysis. Strahlenther Onkol 191 (2015), 125–132.
52. 52 Stauder, M.C., Macdonald, O.K., Olivier, K.R., et al. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 99 (2011), 166–171.